Lucira Health, Inc.
LHDXDelisted- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001652724
Lucira Health, Inc. was delisted in 2023; its insiders filed their last Form 4 on Mar 13, 2023; 29 institutions reported holding it in 13F filings for Q4 2022, worth $1.04M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 29
- Q4 2022, +1 vs. previous quarter
- 13F value
- $1.04M
- Reported value at the end of Q4 2022
- Superinvestors holding
- 0
- At the end of Q4 2022
Superinvestors holding LHDX, Q4 2022
No superinvestor reported holding LHDX at the end of Q4 2022.
Latest insider trades
Open-market purchases and sales by Lucira Health, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 13, 2023 (view filing)5:10 PM ET | Mar 3-7 | 10 daysLate | Narido Richard ClavanoChief Financial Officer | SSale | −29.4K | $1.00 | −$29.4K | −27.4%77.9K after | 5 lots |
| Mar 13, 2023 (view filing)5:09 PM ET | Mar 3-7 | 10 daysLate | Collins Kevin WalterChief Revenue Officer | SSale | −111.8K | $0.6604 | −$73.8K | −32.3%234.9K after | 2 lots |
| Mar 13, 2023 (view filing) | Mar 3 | 10 daysLate | Engelson Erik T.President and Chief Executive | SSale | −634.7K | $1.04 | −$657.3K | −96.5%23.3K after | 2 lots |
| Mar 13, 2023 (view filing) | Mar 3 | 10 daysLate | Allen Anthony JosephChief Operations Officer | SSale | −8.40K | $1.00 | −$8.40K | −5.8%136.5K after | |
| Feb 21, 2023 (view filing)12:38 PM ET | Feb 16 | 5 days | Kashmolah GhaziEx VP & Chief Quality Officer | SSale | −5.03K | $0.27 | −$1.36K | −3.6%134.1K after | |
| Dec 22, 2022 (view filing)2:24 PM ET | Dec 20 | 2 days | Allen Anthony JosephChief Operations Officer | SSale | −4.26K | $0.16 | −$682.08 | −2.9%144.9K after | |
| Dec 9, 2022 (view filing)4:24 PM ET | Nov 21 | 18 daysLate | Allen Anthony JosephChief Operations Officer | SSale | −34.4K | $0.33 | −$11.4K | −18.8%149.2K after | 2 lots |
| Dec 9, 2022 (view filing)4:17 PM ET | Nov 28 | 11 daysLate | Kashmolah GhaziEx VP & Chief Quality Officer | SSale | −7.54K | $0.42 | −$3.17K | −5.1%139.1K after | |
| Dec 9, 2022 (view filing)4:15 PM ET | Nov 17 | 22 daysLate | Kashmolah GhaziEx VP & Chief Quality Officer | SSale | −33.2K | $0.3724 | −$12.4K | −18.5%146.6K after | 2 lots |
| Dec 6, 2022 (view filing)4:21 PM ET | Dec 1 | 5 daysLate | Narido Richard ClavanoInterim CFO | SSale | −1.58K | $0.36 | −$569.88 | −1.5%107.3K after |
Top 10 13F holders, Q4 2022
The largest institutional positions in Lucira Health, Inc. at the end of Q4 2022; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Eclipse Ventures, LLC | 6,223,795 | $690.8K | 0.62% | 00.0% | Unchanged |
| EPIQ Capital Group, LLC | 725,675 | $80.5K | 0.05% | −13,011,695−94.7% | Reduced |
| Vanguard Group Inc | 623,488 | $69.3K | 0.00% | −8,279−1.3% | Reduced |
| Citigroup Inc | 436,840 | $48.5K | 0.00% | −181,803−29.4% | Reduced |
| Balyasny Asset Management LLC | 271,030 | $30.1K | 0.00% | −55,168−16.9% | Reduced |
| Morgan Stanley | 207,755 | $23.1K | 0.00% | −4,399−2.1% | Reduced |
| Papp L Roy & Associates | 150,699 | $16.7K | 0.00% | +36,205+31.6% | Added |
| Bridgeway Capital Management, LLC | 110,500 | $12.3K | 0.00% | −14,200−11.4% | Reduced |
| Consilio Wealth Advisors, LLC | 90,199 | $10.0K | 0.01% | −7,319−7.5% | Reduced |
| Geode Capital Management, LLC | 95,621 | $10.0K | 0.00% | 00.0% | Unchanged |